Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity

Journal of Molecular Medicine

Volumn 91, Issue 4, 2013, Pages 459-472

  Shibina, Anastasia ^a,e   Seidel, Diana ^a,b   Somanchi, Srinivas S ^c   Lee, Dean A ^c   Stermann, Alexander ^b   Maurer, Barry J ^a   Lode, Holger N ^b   Reynolds, C Patrick ^a   Huebener, Nicole ^a,b,d  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e Internal Medicine Department of Hematology/Oncology (Clinic 1)   (Germany)

Author keywords

ADCC; ch14.18; Fenretinide; Immunotherapy; Neuroblastoma

Indexed keywords

FENRETINIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RISK; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; COMPLEMENT SYSTEM PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; FENRETINIDE; GANGLIOSIDES; HUMANS; KILLER CELLS, NATURAL; MICE; NEUROBLASTOMA; RECEPTORS, DEATH DOMAIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879600767     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-012-0958-0     Document Type: Article

References (38)

1. Westermann F, Schwab M (2002) Genetic parameters of neuroblastomas. Cancer Lett 184:127-147
2. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman S, Chen H, Smith M, Anderson B, Villablanca J, Matthay KK et al (2010) Chimeric anti-GD2 antibody with GM-CSF, IL2 and 13-cis retinoic acid for high-risk neuroblastoma: a Children's Oncology Group (COG) phase 3 study. N Engl J Med 363(14):1324-1334
3. Schulz G, Cheresh DA, Varki NM, Yu A, Staffileno LK, Reisfeld RA (1984) Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44(12 Pt 1):5914-5920
4. Svennerholm L, Bostrom K, Fredman P, Jungbjer B, Lekman A, Mansson JE, Rynmark BM (1994) Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1214(2):115-123
5. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, Reisfeld RA, Niethammer D (1992) A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35(3):199-204
6. Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R (2006) FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 24(18):2885-2890
7. Cullen SP, Martin SJ (2008) Mechanisms of granule-dependent killing. Cell Death Differ 15(2):251-262
8. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME (1998) Apoptosis signaling by death receptors. Eur J Biochem 254(3):439-459
9. Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7(12):1001-1012
10. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB et al (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17(7):1065-1071
11. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24(21):3423-3430
12. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP (1999) Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91(13):1138-1146
13. Illuzzi G, Bernacchioni C, Aureli M, Prioni S, Frera G, Donati C, Valsecchi M, Chigorno V, Bruni P, Sonnino S et al (2010) Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl)retinamide in human ovarian cancer cells. J Biol Chem 285(24):18594-18602
14. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B et al (2005) Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 65(24):11667-11675
15. Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, Taguchi Y, Iwai K, Tashima M, Uchiyama T, Okazaki T (2003) Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin Cancer Res 9(1):415-423
16. Gouaze-Andersson V, Cabot MC (2006) Glycosphingolipids and drug resistance. Biochim Biophys Acta 1758(12):2096-2103
17. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC (2000) Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J Biol Chem 275(10):7138-7143
18. Lovat PE, Di SF, Corazzari M, Fazi B, Donnorso RP, Pearson AD, Hall AG, Redfern CP, Piacentini M (2004) Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 96(17):1288-1299
19. White DE, Burchill SA (2010) Fenretinide-dependent upregulation of death receptors through ASK1 and p38alpha enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours. Br J Cancer 103:1380-1390
20. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ (2000) Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol 35:597-602
21. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, Toji LH, Ohno T, Tanabe H, Arlett CF et al (2001) Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 98(14):8012-8017
22. Somanchi SS, Senyukov VV, Denman CJ, Lee DA (2011) Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp (48). doi: 10.3791/2540
23. Warren HS, Rana PM (2003) An economical adaptation of the RosetteSep procedure for NK cell enrichment from whole blood, and its use with liquid nitrogen stored peripheral blood mononuclear cells. J Immunol Methods 280(1-2):135-138
24. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De BB et al (2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9(6):2032-2039
25. Deng W, Li R, Ladisch S (2000) Influence of cellular ganglioside depletion on tumor formation. J Natl Cancer Inst 92(11):912-917
26. Marachelian A, Kang MH, Hwang K, Villablanca JG, Groshen S, Matthay KK, Maris JM, Desantis KB, Reynolds CP, Maurer BJ (2009) Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial. J Clin Oncol 27:15S, abstr 10009
27. Hoon DS, Kuo CT, Wen S, Wang H, Metelitsa L, Reynolds CP, Seeger RC (2001) Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. Am J Pathol 159(2):493-500
28. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP (2008) Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100:580-595
29. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, Sternberg A, Hank JA, Seeger R, Reaman GH et al (2009) Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 27(1):85-91
30. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C et al (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388(6638):190-195
31. Kavuri SM, Geserick P, Berg D, Dimitrova DP, Feoktistova M, Siegmund D, Gollnick H, Neumann M, Wajant H, Leverkus M (2011) Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex. J Biol Chem 286(19):16631-16646
32. Zeng Y, Huebener N, Fest S, Weixler S, Schroeder U, Gaedicke G, Xiang R, Schramm A, Eggert A, Reisfeld RA et al (2007) Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 67(5):2331-2338
33. Cheung NK, Modak S (2002) Oral (1→3),(1→4)-beta-d-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8(5):1217-1223
34. Prinetti A, Basso L, Appierto V, Villani MG, Valsecchi M, Loberto N, Prioni S, Chigorno V, Cavadini E, Formelli F et al (2003) Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J Biol Chem 278(8):5574-5583
35. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP (2000) Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92(23):1897-1909
36. Kouhara J, Yoshida T, Nakata S, Horinaka M, Wakada M, Ueda Y, Yamagishi H, Sakai T (2007) Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. Int J Oncol 30(3):679-687
37. Cuello M, Coats AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer MJ, Lipkowitz S (2004) N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 11(5):527-541
38. Bahram S, Inoko H, Shiina T, Radosavljevic M (2005) MIC and other NKG2D ligands: from none to too many. Curr Opin Immunol 17(5):505-509